FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Caris Life Sciences, Inc. CAI

Promising (early) (graded 2026-09-01, not re-checked)   broader-coverage candidate · Caris Life Sciences, Inc.

On FrontierLab's discovery record since 2026-06-15 (16 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-01), not the curated Frontier signal.
⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)85.4%
Gross margin69.7%
Gross profits / assets0.56
Rule of 40100.9
Net margin15.5%
Cash runway (months)—
PEG—
Price / sales7.3

Quality checklist

Fundamentals — snapshot as of 2026-09-01

StageEarly
Share issuance (YoY)2.5% · modest issuance
Moat—
TAM—
P/E (trailing)71.2
EPS (trailing)$0.36
Burn multiple—
Gross-margin trend (pts)16.2
Cash / assets0.65
Net debt / EBITDA-1.4
Statements as ofQ2 FY2026 · filed 2026-08-05

Momentum context — a snapshot from 2026-09-01, not current

Price at surface$25.49 (as of 2026-09-01)
52-week range$14.19 – $38.68
% off 52-wk high-34.1%
RSI (14)65
Relative volume1×

Risk flags

Parabolic one-day spike (+22%) in the last month — extreme single-day moves tend to mean-revert.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-01 (end-of-day). How grades are computed →